Hyperlipemia and oxidized LDL (ox-LDL) are important independent cardiovascular risk factors. Ox-LDL has been shown to stimulate vascular smooth muscle cell (VSMC) proliferation. However, the effects of hyperlipemia and the molecular mechanisms mediating hyperlipemia and ox-LDL effects on VSMC growth are poorly understood. The helix-loop-helix (HLH) transcription factor, Id3, is a redox-sensitive gene expressed in VSMC in response to mitogen stimulation and vascular injury. Accordingly, we hypothesize that Id3 is an important mediator of ox-LDL and hyperlipemia-induced VSMC growth. Aortas harvested from hyperlipemic pigs demonstrated significantly more Id3 than normolipemic controls. Primary VSMC were stimulated with ox-LDL, native LDL, sera from hyperlipemic pigs, or normolipemic pigs. VSMC exposed to hyperlipemic sera demonstrated increased Id3 expression, VSMC growth and S-phase entry and decreased p21cip1 expression and transcription. Cells stimulated with ox-LDL demonstrated similar findings of increased growth and Id3 expression and decreased p21cip1 expression. Moreover, the effects of ox-LDL on growth were abolished in cells devoid of the Id3 gene. Results provide evidence that the HLH factor Id3 mediates the mitogenic effect of hyperlipemic sera and ox-LDL in VSMC via inhibition of p21cip1 expression, subsequently increasing DNA synthesis and proliferation.

Keywords:
Hypercholesterolemia, Muscle, smooth, Atherosclerosis, Oxidized LDL, Transcription factors
1.
Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Internal Med 2001;161:1413–1419.
2.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
3.
Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM: The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831–842.
4.
Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462–2478.
5.
Lafont A, Libby P: The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J Am Coll Cardiol 1998;32:283–285.
6.
Lusis AJ: Atherosclerosis. Nature 2000;407:233–241.
7.
Braganza DM, Bennett MR: New insights into atherosclerotic plaque rupture. Postgrad Med J 2001;77:94–98.
8.
Han CY, Pak YK: Oxidation-dependent effects of oxidized LDL: proliferation or cell death. Exp Mol Med 1999;31:165–173.
9.
Bjorkerud B, Bjorkerud S: Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 1996;16:416–424.
10.
Auge N, Pieraggi MT, Thiers JC, Negre-Salvayre A, Salvayre R: Proliferative and cytotoxic effects of mildly oxidized low-density lipoproteins on vascular smooth-muscle cells. Biochem J 1995;309:1015–1020.
11.
Chatterjee S: Role of oxidized human plasma low density lipoproteins in atherosclerosis: effects on smooth muscle cell proliferation. Mol Cell Biochem 1992;111:143–147.
12.
Chai YC, Howe PH, DiCorleto PE, Chisolm GM: Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J Biol Chem 1996;271:17791–17797.
13.
Watanabe T, Pakala R, Katagiri T, Benedict CR: Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens 2001;19:1065–1073.
14.
Kusuhara M, Chait A, Cader A, Berk BC: Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 1997;17:141–148.
15.
Zettler ME, Prociuk MA, Austria JA, Massaeli H, Zhong G, Pierce GN: OxLDL stimulates cell proliferation through a general induction of cell cycle proteins. Am J Physiol 2003;284:H644–H653.
16.
Prabhu S, Ignatova A, Park ST, Sun XH: Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol 1997;17:5888–5896.
17.
Peverali FA, Ramqvist T, Saffrich R, Pepperkok R, Barone MV, Philipson L: Regulation of G1 progression by E2A and Id helix-loop-helix proteins. EMBO J 1994;13:4291–4301.
18.
Olson EN: MyoD family: a paradigm for development? Genes Dev 1990;4:1454–1461.
19.
Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, Baltimore D, Weintraub H: Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 1991;66:305–315.
20.
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018–1021.
21.
Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG: Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998;82:396–403.
22.
Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG: Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA 1996;93:7905–7910.
23.
Matsumura ME, Li F, Berthoux L, Wei B, Lobe DR, Jeon C, Hammarskjold ML, McNamara CA: Vascular injury induces posttranscriptional regulation of the Id3 gene: cloning of a novel Id3 isoform expressed during vascular lesion formation in rat and human atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:752–758.
24.
Mueller C, Baudler S, Welzel H, Bohm M, Nickenig G: Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin-II-induced cell growth. Circulation 2002;105:2423–2428.
25.
Nickenig G, Baudler S, Muller C, Werner C, Werner N, Welzel H, Strehlow K, Bohm M: Redox-sensitive vascular smooth muscle cell proliferation is mediated by GKLF and Id3 in vitro and in vivo. FASEB J 2002;16:1077–1086.
26.
Gerrity RG, Natarajan R, Nadler JL, Kimsey T: Diabetes-induced accelerated atherosclerosis in swine. Diabetes 2001;50:1654–1665.
27.
Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753–766.
28.
Nordin FG, Hedblad B, Berglund G, Nilsson J: Plasma oxidized LDL: a predictor for acute myocardial infarction? J Int Med 2003;253:425–429.
29.
Forrest ST, Barringhaus KG, Perlegas D, Hammarskjold ML, McNamara CA: Intron retention generates a novel Id3 isoform that inhibits vascular lesion formation. J Biol Chem 2004;279:32897–32903.
30.
Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262–1270.
31.
Ohlsson BG, Englund MC, Karlsson AL, Knutsen E, Erixon C, Skribeck H, Liu Y, Bondjers G, Wiklund O: Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. J Clin Invest 1996;98:78–89.
32.
Chatterjee S, Bhunia AK, Snowden A, Han H: Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p44 mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells. Glycobiology 1997;7:703–710.
33.
Rao GN, Alexander RW, Runge MS: Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 1995;96:842–847.
34.
Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ: Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993;91:2572–2579.
35.
Yeh K, Lim RW: Genomic organization and promoter analysis of the murine Id3 gene. Gene 2000;254:163–171.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.